课题基金 / 基金详情

PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED

PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED
单独/联合使用氢脲的 I/II 期给药安全性和抗病毒活性
批准号：
6117135
负责人：
GILDON N BEALL
金额：
$3.89万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6117135
关键词：
2'3' dideoxyinosine AIDS therapy HIV infections antiAIDS agent antiviral agents clinical research clinical trial phase I combination chemotherapy dosage drug screening /evaluation gastrointestinal drug absorption human immunodeficiency virus human subject human therapy evaluation hydroxyurea outcomes research virus load

项目摘要

项目成果

GILDON N BEALL的其他基金

相似基金

相关文献

中文摘要
翻译
为了测试两种剂量的药物，羟基脲，单独给药或 与另一种药物DDI一起用于艾滋病毒感染者。这 研究还将观察是否单独或与DDI一起给予羟基脲 减少艾滋病毒感染者血液中的病毒量， 与单独给予DDI相比。此外，DDI和羟基脲是如何 吸收到体内的物质也将被研究。已使用羟基脲 在大量的镰状细胞病患者中， 人是新的，是有限的。
英文摘要
To test the safety of two doses of a drug, hydroxyurea, given alone or together with another drug, DDI, in persons infected with the HIV. This study also will see if hydroxyurea given alone or together with DDI decreases the amount of virus in the blood of HIV-infected persons as compared to DDI given alone. In addition, how DDI and hydroxyurea are absorbed into the body will also be looked at. Hydroxyurea has been used in a large number of sickle cell patients, but its use in HIV-infected persons is new and has been limited.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART
ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN
PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED
海外基金